FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides! Update as of 4.15.26 from the FDA. We will know more in July. This will allow these previously labeled category 2 research peptides to category 1 and allowable for compounding by BPC 157 Orthopedic Use of BPC 157 Sports Med Review